Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,179.4
-1.8 (-0.06%)

 

  • STI Straits Times Index
    3,179.4
    -1.8 (-0.06%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,550.9
    -0.7 (-0.05%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,149.6
    -790.8 (-2.83%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,976.5
    -84.2 (-2.75%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,379.4
    163.7 (0.71%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,105.4
    -5.8 (-0.09%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,185.3
    8.6 (0.39%)
    Index delayed 20 minutes
  • XAO XAO
    7,135.9
    37.5 (0.53%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,113.7M
  • Value: 704.3M
  • Rise: 180
  • Fall: 140
  • Unch: 496

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Medtecs Intl0.187+0.015
Healthway Med0.044-0.002
AsiaMedic0.017-
UG Healthcare0.345+0.095
Golden Agri-Res0.215-0.010
Thomson Medical0.063-
Rex Intl0.174+0.006
MarcoPolo Marine0.022+0.001
Genting Sing0.870-0.005
Ntegrator Intl0.011-

World Indices

World Indices
Name Last Change
Nasdaq 9,269.7 +130.4
HSI 27,159.3 -781.2
HSCEI 10,609.6 -359.6
Jakarta 6,109.1 -2.1
Nikkei 225 23,379.4 +163.7
SSE Comp 2,976.5 -84.2
Shanghai A 3,118.9 -88.2
Shanghai B 248.6 -8.9
PSE Comp 0.0
KOSPI 2,185.3 +8.6

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

RECRO PHARMA INC RECRO PHARMA INC
Updated on 28 Jan 2020 (End of trading day)
Last (USD): 16.400 Change: +0.630 High: 16.490 Remarks: -
Change (%): +3.99 Low: 15.720
Open 15.860 Yesterday's Close 15.769999999999998
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 209,483 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -3.50734 Trailing EPS (USD) e -2.21805 NAV (USD) b -0.8740
PE a - Trailing PE f - Price / NAV b -18.7643
Dividend (USD) d - Cash In Hand (USD) g 1.6693 Issued & Paid-up Shares c 22,730,300
Dividend Yield (%) d - Price / Cash In Hand g 9.824 Treasury Shares h -
Beta - 75 Daysi 0.674 R-Squared - 75 Days(%)i 0.13 Market Cap (M) 372.777
Beta - 500 Daysi 0.178 R-Squared - 500 Days (%)i 0.20 Enterprise Value (M) 445.132
Piotroski F Score 2 Exchange Code REPH Par Value ( $ ) n.a.
52 Weeks Volatility (%) 75.39 Free Float (%) 84.3
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 12 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference RECRO PHARMA INC NASDAQ 372.777 - - -18.7643 -
Industry Biotechnology NASDAQ 2,348.378 361.842 92.382 5.8406 0.755
Local Peer AMGEN INC NASDAQ 133,596.331 15.916 16.561 12.2263 2.488
Local Peer GILEAD SCIENCES INC NASDAQ 81,425.054 14.927 30.236 3.9519 3.590
Local Peer VERTEX PHARMACEUTICAL NASDAQ 59,651.086 28.454 27.825 11.3548 -
Local Peer BIOGEN INC NASDAQ 50,875.622 11.483 9.429 3.6350 -
Local Peer ILLUMINA INC NASDAQ 46,199.160 55.931 47.481 10.4076 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 37,778.597 15.455 17.619 3.5965 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 23,671.498 305.045 16.100 2.2833 -
Local Peer SEATTLE GENETICS INC NASDAQ 19,354.621 - - 10.8758 -
Local Peer INCYTE CORPORATION NASDAQ 16,469.255 150.414 40.668 6.7984 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 15,427.991 - - 5.0182 -
Local Peer GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 14,891.517 - 47.981 5.3877 -
Local Peer ALNYLAM PHARMACEUTICALS INC NASDAQ 12,790.133 - - 7.9586 -
Other Local Peers EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), 10X GENOMICS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), MODERNA INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), FIBROGEN INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), NATERA INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), ALKERMES PLC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), VIELA BIO INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), EPIZYME INC (NASDAQ), XENCOR INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ALECTOR INC (NASDAQ), INSMED INC (NASDAQ), REGENXBIO INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), CORTEXYME INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), NEXTCURE INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), DERMIRA INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), XBIOTECH INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), INTREXON CORP (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), OMEROS CORP (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), RETROPHIN INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), AVROBIO INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), KURA ONCOLOGY INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), AGENUS INC (NASDAQ), MACROGENICS INC (NASDAQ), MERUS B V (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), COMPUGEN (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), CABALETTA BIO INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), ANAPTYSBIO INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), PERSONALIS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), NOVAVAX INC (NASDAQ), GERON CORP (NASDAQ), MEDICINOVA INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), KAMADA (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), ATHERSYS INC (NASDAQ), IMV INC (NASDAQ), AFFIMED N V (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), XOMA CORP (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), CHIASMA INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ARAVIVE INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), VERASTEM INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), SAVARA INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), VACCINEX INC (NASDAQ), CHIMERIX INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), OTONOMY INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), ORGENESIS INC (NASDAQ), SESEN BIO INC (NASDAQ), EQUILLIUM INC (NASDAQ), TREVENA INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), SYNLOGIC INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), VERMILLION INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SOLIGENIX INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), CURIS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), INMUNE BIO INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), RESTORBIO INC (NASDAQ), ADVAXIS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ZAFGEN INC (NASDAQ), EVOGENE LTD (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), OCUGEN INC (NASDAQ), VAXART INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), SOPHIRIS BIO INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), ATYR PHARMA INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), TROVAGENE INC (NASDAQ), PRECIPIO INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), TOCAGEN INC (NASDAQ), BIOCEPT INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), SENESTECH INC (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), OPGEN INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), SPHERIX INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ)
Global Peer CSL ASX 141,910.746 52.894 52.894 18.9640 0.849
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,041.754 85.575 25.249 5.6954 0.701
Global Peer SINO BIOPHARM HKEx 139,085.908 12.980 13.472 4.1421 0.662
Global Peer WUXI BIO HKEx 131,778.133 176.432 137.929 13.5648 -
Global Peer BEIGENE HKEx 95,161.500 - - 9.4948 -
Global Peer Lonza SGX 5,937.453 6.613 6.613 0.6568 4.787
Global Peer GENSCRIPT BIO HKEx 34,558.260 207.825 - 9.7455 -
Global Peer 3SBIO HKEx 26,568.086 17.563 21.377 2.6186 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,878.038 45.902 669.311 2.7807 -
Other Global Peers ALPHAMAB-B (HKEx), HAOHAI BIOTEC (HKEx), POLYNOVO LIMITED (ASX), MYOVANT SCIENCES LTD (NYSE), MESOBLAST LTD (ASX), FRONTAGE (HKEx), CKLIFE SCIENCES (HKEx), NANOVIRICIDES INC (NYSE American), AVITA MEDICAL LTD (ASX), VIVA BIOTECH (HKEx), ASCENTAGE-B (HKEx), KADMON HLDGS INC (NYSE), SINOMAB BIO-B (HKEx), ARCUS BIOSCIENCES INC (NYSE), ASCLETIS-B (HKEx), ESSEX BIO-TECH (HKEx), LEE'S PHARM (HKEx), DPHARMA (Bursa), NEXT SCIENCE LTD (ASX), PFENEX INC (NYSE American), TELIX PHARMACEUTIC (ASX), BBI LIFE SCI (HKEx), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), LINEAGE CELL THERAPEUTICS INC (NYSE American), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), UNI-BIO GROUP (HKEx), RESAPP HEALTH LIMITED (ASX), CEL-SCI CORP (NYSE American), PYC THERAPEUTICS LIMITED (ASX), ENZO BIOCHEM INC (NYSE), 22ND CENTURY GROUP INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), IMUGENE LIMITED (ASX), CYNATA THERAPEUTICS LTD (ASX), IMMUTEP LTD (ASX), ONCOSIL MEDICAL LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), ORTHOCELL LIMITED (ASX), CT ENTERPRISE (HKEx), ISORAY INC (NYSE American), INVEX THERAPEUTICS LTD NPV (ASX), BIOSINO BIO-TEC (HKEx), BIOTRON (ASX), GENETIC TECHNOLOGIES (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ACTINOGEN MEDICAL LTD (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), REGENT PACIFIC (HKEx), ANTEOTECH LIMITED (ASX), BIONOMICS LTD (ASX), MEMPHASYS LTD (ASX), TALI DIGITAL LIMITED (ASX), IBIO INC (NYSE American), EXTRAWELL PHAR (HKEx), CCP TECHNOLOGIES LTD (ASX), ORAGENICS INC (NYSE American), RHINOMED LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), PROTEOMICS INTL LABORATORIES LTD (ASX), IMMURON LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), CELLMID LIMITED (ASX), PATRYS LIMITED (ASX), Suntar Eco-City^ (SGX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), REGENEUS LTD (ASX), ADALTA LTD (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), HOLISTA COLLTECH LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), SIENNA CANCER DIAGNOSTICS LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), AIM IMMUNOTECH INC (NYSE American), LIVING CELL TECHNOLOGIES (ASX), HAO WEN HLDGS (HKEx), BENITEC BIOPHARMA LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), BIOXYNE LIMITED (ASX), MEDIBIO LIMITED (ASX), QT Vascular (SGX), MGRC (Bursa), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), BPH ENERGY LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.040
-0.24 %
10 Days -+0.120
+0.74 %
20 Days --1.930
-10.53 %
Medium Term Return 3 Months -+3.896
+31.16 %
6 Months -+7.708
+88.68 %
1 Year -+9.247
+129.27 %
Long Term Return 2 Years -+8.604
+110.36 %
3 Years -+9.456
+136.18 %
5 Years -+13.439
+453.87 %
Annualised Return Annualised --
+40.83 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 5.007 - 19.000 Change From 1 Year Low +11.393 % Change From 1 Year Low (%) +227.55
Change From 1 Year High -2.600 % Change From 1 Year High (%) -13.68
2 Years Range 4.328 - 19.000 Change From 2 Years Low +12.072 % Change From 2 Years Low (%) +278.95
Change From 2 Years High -2.600 % Change From 2 Years High (%) -13.68
5 Years Range 2.626 - 19.000 Change From 5 Years Low +13.774 % Change From 5 Years Low (%) +524.62
Change From 5 Years High -2.600 % Change From 5 Years High (%) -13.68
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Recro Pharma, Inc. is a pharmaceutical company, which engages in the research and development of non-opioid therapeutics for the treatment of acute post operative pain. It operates through the Acute Care, and Contract Development and Manufacturing (CDMO) business segment. The Acute Care segment focuses on developing innovative products for hospital and related settings. The CDMO segment leverages the company's formulation expertise to develop and manufacture pharmaceutical products using the company's proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Its products include Meloxicam, Dexmedetomidine, and Fadolmidine. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Malvern, PA.

Historical Price Data

Date Open High Low Close Volume VWAP
28 Jan 2020 15.860 16.490 15.720 16.400 209,483 -
27 Jan 2020 15.650 16.175 15.600 15.770 356,511 -
24 Jan 2020 16.270 16.450 15.730 15.880 160,076 -
23 Jan 2020 16.310 16.410 16.080 16.220 137,350 -
22 Jan 2020 16.480 16.680 16.120 16.440 234,297 -
21 Jan 2020 16.100 16.910 15.840 16.380 308,949 -
17 Jan 2020 16.370 16.470 15.930 16.100 205,391 -
16 Jan 2020 16.340 16.850 16.250 16.265 325,722 -
15 Jan 2020 16.460 16.828 16.200 16.280 352,862 -
14 Jan 2020 16.480 17.124 16.330 16.420 718,010 -
13 Jan 2020 16.490 16.590 16.215 16.480 332,906 -
10 Jan 2020 16.640 16.830 16.435 16.490 173,159 -
09 Jan 2020 16.460 16.990 16.350 16.780 172,997 -
08 Jan 2020 16.950 17.150 16.370 16.470 181,619 -
07 Jan 2020 17.040 17.160 16.720 17.000 149,297 -
06 Jan 2020 16.910 17.480 16.640 17.080 235,156 -
03 Jan 2020 17.240 17.480 16.650 17.030 210,047 -
02 Jan 2020 18.460 18.520 17.140 17.530 344,517 -
31 Dec 2019 18.820 19.000 18.190 18.330 275,527 -
30 Dec 2019 18.310 18.940 17.790 18.820 671,574 -
27 Dec 2019 18.450 19.000 17.639 18.230 255,781 -
26 Dec 2019 18.060 18.640 18.060 18.360 443,819 -
Summary
Current 2 Weeks
(14 Jan 2020 to 28 Jan 2020)
16.480 17.124 15.600 16.400 3,008,651 -
Previous 2 Weeks
(30 Dec 2019 to 13 Jan 2020)
18.310 18.940 15.600 16.480 2,746,799 -
4 Weeks from
(29 Nov 2019 to 27 Dec 2019)
16.190 17.124 15.600 18.230 6,798,306 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.